Drug intelligence / Profile preview

KAN-NEURO-03

Development stage: Preclinical
Lead developer: Kantify
Modality: Small Molecules

Overview

KAN-NEURO-03 is a preclinical-stage, first-in-class small molecule drug candidate being developed for the treatment of rare neurological and neuromuscular disorders. Discovered using Kantify's proprietary AI platform, Sapian, the drug acts as a modulator of an orphan sodium channel. By targeting a previously undruggable sodium channel, KAN-NEURO-03 represents a novel therapeutic approach for orphan conditions with significant unmet medical needs. The program is currently in the lead optimization phase and is being developed by Kantify in partnership with INSERM-ITN and INSERM-IGF.

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on KAN-NEURO-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAN-NEURO-03.

Explore the full profile